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Abstract
Purpose: Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature ovarian
failure; the exact mechanism by which this occurs is uncertain. Here, two commonly used chemotherapeutic agents
(cisplatin and doxorubicin) were added to a mouse ovary culture system, to compare the sequence of events that leads to
germ cell loss. The ability of imatinib mesylate to protect the ovary against cisplatin or doxorubicin-induced ovarian damage
was also examined.
Experimental design: Newborn mouse ovaries were cultured for a total of six days, exposed to a chemotherapeutic agent
on the second day: this allowed for the examination of the earliest stages of follicle development. Cleaved PARP and TUNEL
were used to assess apoptosis following drug treatment. Imatinib was added to cultures with cisplatin and doxorubicin to
determine any protective effect.
Results: Histological analysis of ovaries treated with cisplatin showed oocyte-specific damage; in comparison doxorubicin
preferentially caused damage to the granulosa cells. Cleaved PARP expression significantly increased for cisplatin (16 fold,
p,0.001) and doxorubicin (3 fold, p,0.01). TUNEL staining gave little evidence of primordial follicle damage with either
drug. Imatinib had a significant protective effect against cisplatin-induced follicle damage (p,0.01) but not against
doxorubicin treatment.
Conclusion: Cisplatin and doxorubicin both induced ovarian damage, but in a markedly different pattern, with imatinib
protecting the ovary against damage by cisplatin but not doxorubicin. Any treatment designed to block the effects of
chemotherapeutic agents on the ovary may need to be specific to the drug(s) the patient is exposed to.
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Introduction
Premature ovarian failure (POF, also termed primary ovarian
insufficiency; POI) is a common long-term adverse effect of
chemotherapy treatment in premenopausal women [1] with
consequences for both fertility and non-reproductive health such
as osteoporosis [2] and cardiovascular disease [3]. The risk of
developing POF is dependent on chemotherapy regimen [4], drug
dosage [5,6] and patient age [7]. Whilst it is well recognised that
chemotherapy treatment can lead to POF due to loss of ovarian
follicles, the exact mechanism by which this occurs is less certain
[8]. Such knowledge is invaluable in the search to develop
potential treatments to protect the ovary from chemotherapy-
induced damage. The aim here is to determine the precise ovarian
effects of two of the drugs commonly used to treat cancers in
premenopausal women, cisplatin and doxorubicin.
By birth, the ovary has a fixed population of germ cells (oocytes)
contained within follicles. These are formed prenatally at the
primordial stage, consisting of an immature oocyte in meiotic
arrest, surrounded by a few flattened somatic (granulosa) cells.
Primordial follicles constitute the resting pool of female germ cells
present for the duration of a female’s reproductive lifespan. At any
one time, a small cohort is activated to grow, with the transition to
the growing primary follicle stage marked by somatic cells
becoming cuboidal and proliferating to fully surround the growing
oocyte. Somatic cells continue to proliferate and form increasing
numbers of layers around the oocyte, thecal cells are recruited
from the interstitial stroma to surround the follicle and, as the
follicle increases in size, fluid-filled patches form within the
granulosa cell layers to create an antral cavity.
Numerous cell types in the ovary may be potential targets for
damage by chemotherapeutic agents. It is often assumed that the
primary cell type damaged is the oocyte within immature follicles,
since ultimately loss of these leads to POF. There is, however,
limited available evidence for this, as most studies showing oocyte
damage used mature ovulated oocytes [9,10], whereas in women,
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what is of importance is damage to oocytes contained within
ovarian follicles. Within follicles, somatic cells could be the
primary target [11,12], leading to germ cell death and hence
follicle loss indirectly. Also of importance is the follicle stage most
at risk from chemotherapy-induced damage. Most studies
examining follicles have focused on loss of primordial follicles
[13,14], as it is this that ultimately leads to POF. However,
reduction of the primordial follicle pool could be due to either
direct primordial follicle damage or to an indirect effect; damage
to more mature, growing follicles would lead to increased
recruitment of primordial follicles out of the resting pool and
hence to premature depletion of that resting follicle reserve [8,15].
Proliferating somatic cells within growing follicles also represent a
more logical target for chemotherapy-induced damage than
mitotically inactive cells. A better understanding of the mechanism
by which chemotherapy-induced follicle loss occurs is vital for the
development of potential protective treatments for those women at
risk.
The work described here examines the effects of two
chemotherapeutic drugs commonly used in the treatment of
premenopausal women, cisplatin and doxorubicin. Cisplatin is a
DNA cross-linking agent commonly used in the treatment of
sarcomas and germ cell tumours. Its precise mechanism of action
is not entirely clear, although it is known to intercalate with DNA
strands causing crosslinking and adduct formation [16]. It is
considered moderately gonadotoxic, and in a postnatal in vitro
mouse ovary model can cause massive oocyte death [17].
Doxorubicin is an anthracycline which intercalates with DNA
and prevents its replication and transcription [9]. It is used to treat
a variety of cancers including breast cancer, lymphomas and
leukaemias and recent evidence suggests that it is moderately
ovotoxic [18]. Mature ovulated oocytes treated with doxorubicin
undergo rapid DNA damage and cytoplasmic changes associated
with apoptosis [10]; its action on immature follicles within the
ovary is less clear although a recent study of human primordial
follicles showed apoptotic damage to both oocytes and granulosa
cells [19].
This work also investigates the ability of imatinib mesylate
(called imatinib hereafter) to protect the ovary against damage
induced by either cisplatin or doxorubicin. Imatinib is a tyrosine
kinase inhibitor, used as the primary treatment for chronic
myeloid leukaemia due to its inhibition of the tyrosine kinase
BCR-ABL [20]. Imatinib can also inhibit c-Abl, PDGF receptor
and c-kit [21], all of which can affect basic cellular function (cell
signalling, proliferation and differentiation) including within
ovarian follicles [22,23]. Some recent work indicates that it has
a protective effect against cisplatin-induced follicle loss [17,24]
although this has been disputed [25]. The ability of imatinib to
protect against doxorubicin-induced ovarian damage is currently
unknown.
The aim of this study was to investigate the mechanisms by
which cisplatin and doxorubicin cause follicle loss using an in vitro
system to culture mouse ovaries. The advantage of using such a
culture controlled environment is that it allows precise determi-
nation of the cell type first damaged by the drugs while allowing
follicles to develop in a highly physiological manner [26]. The
system used here, culturing ovaries from newborn mice, supports
follicle formation, growth initiation and development to the
primary-secondary phase [27].
Materials and Methods
Animals
Ethics statement. This work was approved by the University
of Edinburgh’s Local Ethical Review Committee. Animals were
provided with food and water ad libitum, and kept in accordance
with UK Home Office regulations. C57Bl6J mice were housed in
an environmentally-controlled room on a 14-hour light, 10-hour
dark photoperiod.
Ovary Culture
Newborn female mice were culled by decapitation and ovaries
dissected out into Leibovitz L-15 dissection medium (Invitrogen,
Paisley UK) supplemented with 3 mg ml21 bovine serum albumin
(Sigma Aldrich Ltd, Dorset UK). Ovaries were cultured on
Whatman Nucleopore membranes (Camlab Ltd, Cambridge UK;
Whatman Nucleopore Polycarbonate Membranes 13 mm 8.0 mm)
floating on 1 ml a-MEM medium (Invitrogen, Paisley UK)
supplemented with 3 mg ml21 bovine serum albumin (Sigma
Aldrich), in a 24 well plate (Greiner Bio-one, Stonehouse UK)
incubated at 37uC, 5% CO2. Information on follicle composition
in control ovaries over the course of the culture period is shown in
Figure S1.
After 24 h in culture (Day 1), medium was supplemented with
varying doses of either cisplatin or doxorubicin-HCl, both from
Sigma Aldrich, both first dissolved in sterile water (Day 2).
Concentration ranges for each drug was determined from
preliminary experiments finding the lowest dose leading to death
of the majority of follicles; cisplatin was added to produce final
concentrations of 0, 0.1, 0.5, 1 or 5 mg ml21 and doxorubicin to
produce final concentrations of 0, 0.01, 0.05, 0.1 or 0.2 mg ml21.
Following the 24 h of drug exposure (Day 2), ovaries were either
snap-frozen for protein extraction, fixed for TUNEL analysis or
moved into drug free culture for a further four days (Days 3–6),
with 50% of medium changed every other day.
For the cultures containing imatinib mesylate (VWR Interna-
tional Ltd UK, dissolved in sterile water), imatinib was added to
produce a final concentration of 3 mg ml21. Dosage was
determined from unpublished preliminary results indicating that
this was the highest dose at which no significant morphological
damage was seen when compared to control cultures. Imatinib
was added to the medium on Days 1 to 3 of culture, with cisplatin
or doxorubicin also added only on Day 2 of culture for 24 hours as
in the previous experiments. Ovaries were then moved into drug-
free culture for a further 3 days (Days 4–6) with 50% of medium
changed every other day.
Protein Extraction and Western Blotting
Frozen ovaries were homogenised in 20 ml lysis buffer
(containing 50 mM HEPES buffer, 10% Triton X, 50 mM NaCl,
Protease inhibitor cocktail and protease inhibitors [I and II], H2O;
all purchased from Sigma Aldrich Ltd except for Protease
inhibitor cocktail which was purchased from Roche Diagnostic
Ltd) and centrifuged at 13000 rpm for 20 mins: supernatant was
used for Western blotting. Approximately 10 mg of protein from
each ovary was loaded onto a 7% acrylamide gel and run at
30 mA at room temperature. Protein was transferred onto a
nitrocellulose membrane and blocked using 5% powdered milk
(w/v) in phosphate buffered saline (PBS, pH7.3, 160 mM NaCl,
3 mM KCl, 8 mM Na2HPO4, 1 mM KH2PO4). PARP rabbit
polyclonal antibody (New England Biolabs, Hertfordshire UK)
was added at 1:1000 dilution: this antibody to PARP detects both
the full length (116 kD) and cleaved (89 kD) form. b-actin rabbit
polyclonal antibody (Abcam, Cambridge UK) was added at
Ovarian Damage from Cisplatin and Doxorubicin
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1:5000 dilution as a loading control. Membranes were then
incubated overnight at 4uC. After washing in PBS, membranes
were incubated with Alexafluor anti-rabbit 750 (Invitrogen, UK)
at 1:2000 for 1 h, membranes re-washed and dried, and imaging
and analysis carried out using a Li-cor scanner and Odyssey v1.2
software (Li-cor Biosciences, US). 89 kD bands were analysed to
determine expression of Cleaved PARP, with 45 kD bands
analysed to determine expression of b-actin.
Histological Follicle Assessment
Ovaries cultured for six days were placed in Bouins fixative for
90 mins, paraffin wax-embedded, sectioned at 5 mm and stained
with haemotoxylin and eosin. Every sixth section was photo-
micrographed and follicle assessment and counts carried out. All
sections were assessed blind as to treatment. For the initial
experiments with cisplatin and doxorubicin, 5 ovaries were
assessed in each treatment group from 6 independent cultures.
For the imatinib experiments, 7 ovaries were assessed for each
treatment from 4 independent cultures.
A follicle was counted if the oocyte had a germinal vesicle
present in the section analysed. All counted follicles were assessed
for stage and health. For stage analysis, follicles were considered to
be at the primordial stages where the oocyte was clearly associated
with only pre-granulosa cells; the transitional stage where the
oocyte was surrounded by granulosa cells some of which were
flattened and some cuboidal; and at the primary stage where the
oocyte was surrounded by a complete layer of cuboidal granulosa
cells. Follicles were also classified by their morphological health,
using standard criteria [28,29]. In detail, a follicle was healthy if: a)
the oocyte was round and contained evenly stained cytoplasm; b)
there were no pyknotic granulosa cells (or no more than 1 for
primary follicles); and c) there was clear attachment between the
oocyte and its surrounding granulosa cells. Any follicle not
considered healthy (not passing all three criteria) was further
categorized as having an unhealthy oocyte only; unhealthy
granulosa cells only; or having both oocyte and granulosa cells
unhealthy. An oocyte was considered to be of poor health if it
exhibited any one of shrunken cytoplasm, heavy or uneven eosin
staining or no attachment between oocyte and its surrounding
somatic cells. The assessment of the health of granulosa cells was
dependent on follicle stage: for primordial and transitional follicles,
a follicle was assessed as unhealthy if it contained any clearly
pyknotic granulosa cell (out of the 3–6 present); for primary
follicles, a follicle was assessed as unhealthy if it contained 2/3 or
more clearly pyknotic granulosa cells (out of the 10–20 present).
Abercrombie correction was applied to raw counts multiplied by
frequency of section counted, in order to estimate total follicle
number [30].
TUNEL Analysis
Newborn mouse ovaries were placed in culture in control
medium, or treated with medium supplemented with 1 mg ml21
cisplatin or 0.1 mg ml21 doxorubicin during Day 2 of culture. The
second highest doses of chemotherapy drugs were used here to
induce an appreciable level of damage, but not the overwhelming
follicle loss seen at the highest doses. At the end of Day 2, ovaries
were washed in PBS (Invitrogen, UK, pH7.4, 1.06 mM KH2PO4,
155.17 mM NaCl, 2.97 mM Na2HPO4.7H2O), fixed in 10%
buffered formalin (Sigma Aldrich Ltd, UK) for 1 h, paraffin wax-
embedded, sectioned at 5 mm and every 12th section taken for
analysis. After dewaxing, sections were permeabilised with 10 ug
ml21 proteinase K in 10 mM Tris/HCl, then labelled with
TUNEL reagents according to manufacturer instructions (Roche
Diagnostics Ltd). Sections were then counterstained with DAPI
(Invitrogen, UK) and mounting medium applied (Vector Labora-
tories, Inc.). Sections were observed and images collected with a
Leica AS6000 fluorescent microscope (Leica Microsystems,
Germany). Sections were then washed in PBS and coverslips
gently removed for subsequent haematoxylin and eosin staining.
Sections were then re-observed and photomicrographs collected
using a Leica DMLB microscope equipped with Leica DFC480
camera (Leica Microsystems, Germany). Image analysis was
performed using ImageJ software.
Statistical Analysis
Graphpad prism was used for statistical analyses. Data
normality was assessed using Kolmogorov Smirnoff tests. In all
instances where raw data were not normally distributed, log
transformation was sufficient to normalise data. Normally
distributed data were then analysed using one way ANOVA to
determine if significant differences were present across treatments,
followed by Bonferroni post-hoc test where ANOVA was
statistically significant, and where analyses compared only planned
treatments (Imatinib experiments). All mean6sem and p values
are listed in Table S1.
Results
Cisplatin and Doxorubicin Induce Follicle Loss and
Unhealthy Follicles
Newborn ovaries were cultured for six days in control medium
or exposed to cisplatin or doxorubicin only on Day 2 of culture
(Fig. 1). Over the six days, most primordial follicles initiated
growth to the transitional or primary stage, with few reaching the
secondary stage. The proportion of follicles deemed morphological
unhealthy significantly increased with dosage for both cisplatin
and doxorubicin (Fig. 1Ai and Bi). To assess whether drug
treatment led to follicle loss, total follicle number was calculated
from histological analyses and log transformed for normality. Both
cisplatin and doxorubicin caused significant follicle loss, but with
different patterns of dose response (Fig. 1Aii and Bii). Cisplatin
induced significant loss of follicles only at the highest concentration
(5 mg ml21; p,0.01, n= 5), which induced poor health in almost
all follicles (Fig. 1A). In contrast doxorubicin resulted in a
significant decrease in follicle number (p,0.05, n= 5) even at a
dose which induced poor health in only around 30–35% of follicles
(0.05 mg ml21; Fig. 1B).
Cisplatin and Doxorubicin Target Different Follicle Stages
As both drug treatments led to increased numbers of unhealthy
follicles, they were further categorized to see if a particular follicle
class was affected by each drug (Fig. 2). Both drugs caused a
reduction in primordial follicle number to the point where, at the
highest doses there were insufficient present to meaningfully
analyse primordial follicle health (mean6sem number of primor-
dial follicles in 5 mg ml21 cisplatin group= 464, and in 0.2 mg
ml21 doxorubicin group= 161, vs control = 60620; n= 5).
Primordial follicle health was, therefore, assessed in a separate
study (see below). Further analysis was possible, though, for
transitional and primary follicles. Cisplatin caused a significant
increase in the percentage of morphologically unhealthy transi-
tional follicles only at the highest dose of cisplatin used (5 mg ml21;
p,0.001; n = 5), while there were a significant percentage of
unhealthy primary follicles at all doses (Fig. 2A). In contrast,
doxorubicin caused a significant increase in the percentage of both
transitional and primary follicles classified as morphologically
unhealthy from the second lowest dose (p,0.05 for transitional,
p,0.001 for primary; n= 5; Fig. 2B).
Ovarian Damage from Cisplatin and Doxorubicin
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Cisplatin and Doxorubicin affect Different Ovarian Cell
Types
In order to determine which specific follicular cell type was
targeted by the two drugs, follicles were further classified as
unhealthy due to: (a) the oocyte only; (b) granulosa cells only; or (c)
both the oocyte and granulosa cells. In ovaries treated with
cisplatin, unhealthy follicles were classified as such primarily due to
oocyte health (Fig. 3A), with significant increases in the percentage
of follicles with morphologically unhealthy oocytes seen at all doses
of cisplatin used (p,0.05 for the lowest doses, p,0.01 for 5 mg
ml21; n = 5). In marked contrast, doxorubicin primarily induced
follicles classified as unhealthy due to the granulosa cell health
(Fig. 3B), with significant increases in the percentage of follicles
with morphologically unhealthy granulosa cells seen at the three
highest doses (p,0.001 for all three doses; n = 5). For both drugs,
follicles in which both the oocyte and granulosa cells were
unhealthy were rarely seen except at the two highest doses (Fig. 3C;
p,0.001 for 5 mg ml21 cisplatin, p,0.01 for 0.2 mg ml21
doxorubicin; n= 5).
Cisplatin and Doxorubicin do not Increase the Number of
TUNEL-positive Primordial Follicles
After six days of culture, ovaries previously treated with high
doses of chemotherapy drugs contained few primordial follicles
(see above). Since a higher percentage of follicles are at the
primordial stage earlier in the culture process (see Figure S1),
apoptosis was analysed in ovaries immediately following drug
exposure at the end of Day 2. TUNEL reaction was then carried
out to identify apoptotic cells, with primordial follicles subse-
quently identified after co-staining with haematoxylin and eosin
(Fig. 4A,B). Primordial follicle number present after treatment
with 0.1 mg ml21 doxorubicin was significantly lower than in
control ovaries (p,0.05, n= 4–5), with a non-significant (p.0.05)
decrease in the number present following treatment with 1 mg
ml21 cisplatin (n = 4–5; Fig. 5A). However, drug-exposure did not
affect the number of primordial follicles positive for TUNEL
staining (mean6sem in control group= 3568, in doxorubicin
group= 43624, and in cisplatin group= 33611; n = 4–5; Fig. 5A),
which likewise was unaffected by the culture process (see Figure
S2). Similarly, there was no change to the oocyte or granulosa cell
distribution of such TUNEL-positive cells within the primordial
follicles following either drug treatment (Fig. 5B). Together, results
provide no evidence for primordial follicle loss in response to
chemotherapy drug-exposure being due to apoptosis.
Cell Death Pathway
Expression of the apoptosis marker cleaved PARP was analyzed
using Western blotting to examine how the two drugs induced
apoptosis (see Figure S3 for example of Western blots). PARP is a
DNA repair protein cleaved in mid/late stage apoptosis. Cisplatin
resulted in a significant dose-dependent increase in cleaved PARP
expression, with the highest dose increasing expression 16-fold
(p,0.001, Fig. 5C,D; n= 3). In contrast, doxorubicin had little
effect, only significantly increasing cleaved PARP expression at the
highest dose, and even then inducing only a 3-fold increase in
expression (p,0.01, n = 3). This difference in cleaved PARP
expression following exposure to the two drugs is despite the
finding that the highest doses of both drugs induced loss of almost
all follicles in both cases (Figs. 1Aii, Bii, 5C,D).
Figure 1. Cisplatin and doxorubicin both lead to loss of follicle health and a reduction in follicle numbers. (A) Cisplatin; (B)
Doxorubicin: (i) Percentage of unhealthy follicles (clear); and (ii) total number of follicles (shaded) in each ovary. Bars denote mean+sem; n= 5 for all
groups, stars denote significant differences relative to control (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0070117.g001
Ovarian Damage from Cisplatin and Doxorubicin
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e70117
Imatinib Cotreatment Protects Follicles against Cisplatin
but not Doxorubicin
Since recent evidence has suggested that the tyrosine kinase
inhibitor imatinib can alleviate cisplatin-induced ovarian damage
(17), ovaries were exposed to imatinib using the present model, to
compare its ability to protect the ovary against damage by both
cisplatin and doxorubicin. Ovaries were treated with either
cisplatin (0.5 mg ml21) or doxorubicin (0.05 mg ml21), with those
mid-range doses chosen as both induced the appearance of a
similar percentage of unhealthy follicles (around 30%), without
causing the extensive damage to the ovary found after exposure to
the highest doses. Drug exposure was limited to Day 2 of culture as
in previous experiments, with imatinib (3 mg ml21) present
throughout Days 1–3 of culture to maximize any potential
protective capacity of the drug. Imatinib treatment alone led to
a small reduction in the percentage of unhealthy follicles when
compared to control although this was not significant (n = 7;
Figs. 4C,D, 6A). Imatinib had a clear protective effect against
damage from cisplatin, reducing the percentage of unhealthy
follicles by 21% (p,0.01; n = 7; Figs. 4E,F, 6A). Imatinib tended
to lead to a reduction in the percentage of unhealthy follicles
present during exposure to doxorubicin (9% reduction), but this
was not significant (Bonferroni adjusted p= 0.6: n = 7; Figs. 4G,H,
6A). The presence of imatinib alone also lead to a higher number
of follicles present in the ovary at the end of culture (p,0.05;
n = 7): the same trend occurred in the cisplatin- and doxorubicin-
treated cultures but was not significant in either case (p.0.05 for
both: Fig. 6B).
Discussion
Chemotherapy treatment has long been associated with POF
and infertility in premenopausal patients. It is often assumed that
chemotherapy drugs directly damage oocytes in the primordial
follicle reserve and that it is this loss that leads to POF. There is,
however, little available evidence for this: instead, chemothera-
peutic drugs could primarily damage the growing population of
ovarian follicles leading to increased growth activation of
primordial follicles and thus premature depletion [15], while
initial site of damage could be either oocytes and/or somatic cells
[8]. The culture system used here allows analysis of the early stages
of follicle development in a highly physiological and controlled
environment. Our results show that cisplatin and doxorubicin lead
to a different pattern of follicle loss/damage and that they act
through different cellular mechanisms. Furthermore, imatinib
provided protection to follicles from cisplatin but not doxorubicin.
Cisplatin and doxorubicin are commonly used in cancer
treatment of premenopausal women and both have been linked
to follicle loss and POF. Data here are consistent with these
findings, showing an increase in unhealthy follicles, and a
reduction in total follicle number, following treatment with either
cisplatin or doxorubicin. Both drugs were used in doses within the
therapeutic range for patients, which are around 0.5–1 mg ml21
for cisplatin [31,32] and about 0.02–0.6 mg ml21 for doxorubicin
[33,34]. As the culture system here supports primordial follicle
formation, activation and maturation through to the primary
stage, the effect of chemotherapy drugs on very specific
populations of follicles could be assessed. Administration of
Figure 2. Cisplatin and doxorubicin affect different follicle classes. Follicles were classified as morphologically unhealthy in cisplatin and
doxorubicin treated ovaries according to follicle type. Effect of (A) Cisplatin or (B) Doxorubicin on the percentage of transitional and primary follicles
classified as morphologically unhealthy. Bars denote mean+sem; n = 5 for all groups, stars denote significant differences relative to control (*p,0.05,
**p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0070117.g002
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chemotherapeutic agents in culture also allowed both dosage and
duration of exposure to be tightly controlled.
Loss of the primordial follicle pool via chemotherapy-induced
damage, whether through direct or indirect action, is an important
consideration, as this loss will directly lead to POF. Here, few
primordial follicles were left after exposure to high levels of
cisplatin or doxorubicin, but TUNEL analysis failed to find
evidence of increased apoptosis within the primordial follicles. The
simplest explanation for this is that the reduction in primordial
follicle numbers after drug exposure is due to growth initiation,
presumably as a result of the death of growing follicles and thus
loss of local growth initiation inhibiting factors, such as anti-
Mu¨llerian hormone (AMH), [35]. These results support those of
[12], who treated mice in vivo with doxorubicin and analysed
ovaries following 24 hours of exposure; they saw little or no
TUNEL-positive cells in primordial follicles, while TUNEL-
positive cells were seen in secondary, preantral and antral follicles.
In contrast to the indirect effect of the drugs on primordial
follicles, direct damage to later stages of follicles was clear, with
cisplatin treatment mainly damaging primary follicles, while
doxorubicin treatment led to unhealthy follicles at both transi-
tional and primary stages, indicating a greater vulnerability of
follicles to doxorubicin as soon as they leave the primordial stage.
Depletion in both primary and primordial follicles has previously
been demonstrated in mouse pups injected with cisplatin [17].
Cisplatin causes cell death primarily through DNA crosslinking
and adduct formation [36]. In cisplatin-treated ovaries, the oocyte
was the primary reason for a follicle being classified as
morphologically unhealthy, suggesting that cisplatin directly
targets the germ cell. Given the importance from an evolutionary
prospective of protecting the integrity of the germ line, it may be
that oocytes are particularly vulnerable to agents causing
overwhelming DNA damage. It is well established that the oocyte
is particularly susceptible to cell death following DNA damage
caused by radiotherapy [37]. It is perhaps not that surprising,
therefore, that oocytes would also be highly susceptible to the
damaging effects of cisplatin. The preferential site of cisplatin
toxicity being the oocyte is perhaps also why follicle health was not
reduced in follicles on initiation of growth (ie transitional follicles),
but manifested at the slightly later primary stage.
Doxorubicin can cause DNA damage and inhibit topoisomerase
enzymes, both of which inhibit DNA replication and cell division.
In contrast to the effect of cisplatin, results here show that
doxorubicin primarily targeted the granulosa cells of follicles. An
in vivo study which used 4 week old female mice injected with a
single dose of doxorubicin also found an increase in granulosa cells
which stained positive for caspase 3, indicating apoptosis [12]. In
contrast to oocytes, granulosa cells are mitotically active, which
may explain their vulnerability to these types of chemotherapy
agents. Doxorubicin induces apoptosis in mature (MII) oocytes
in vitro [9,10] and a recent study has shown that oocytes collected
from antral follicles and cultured in vitro are also highly susceptible
to such damage [38]. The oocytes examined here were not
mature, but instead contained within non-growing or early-
growing follicles, which may explain why they are less sensitive to
doxorubicin in this system. This model is, though, possibly more
relevant to patients, since the oocytes required to maintain long
term fertility will also be contained within non-growing follicles. A
recent study of human primordial follicles treated in vitro with
doxorubicin showed damage to both oocytes and granulosa cells,
although that study used much higher concentrations of doxoru-
bicin than were used here, with levels in this study encompassing
those found in the serum of patients [19,33,34].
PARP is a DNA repair protein which detects the presence of
single and double strand DNA breaks. When DNA damage is
minor, PARP activates enzymatic machinery such as DNA
polymerase and ligase, allowing repair of these breaks [39].
Where DNA damage is extensive, activation of PARP can lead to
either necrotic or apoptotic cell death. PARP can be cleaved by
caspase-dependent or independent mechanisms, leading to cell
death. Although there is some evidence that PARP cleavage is not
essential to the process of apoptosis, it is generally considered one
of the hallmarks of apoptotic cell death [40]. Cisplatin caused a
dose-dependent and robust increase in cleaved PARP expression,
in marked contrast to doxorubicin which led to only a small
increase in expression and only at the highest dose used, further
evidence that cisplatin and doxorubicin are causing cell death
through quite different mechanisms.
The fact that the two cytotoxic agents cause POF in different
ways should not be surprising. The mechanism of action and
toxicities of different chemotherapeutic agents are discrete and
while it may be that some of the doxorubicin effect on the growing
follicle pool is due to a cytotoxic effect on the dividing granulosa
cells, our data suggest this is not the cause of cisplatin-induced
damage. This raises the question of how a cytotoxic agent such as
cisplatin affects non-dividing cells. It is, however, known that
neuropathy is one of the main toxicities of cisplatin therapy despite
the fact that neurones are not actively dividing. The mechanism by
which cisplatin cause neurotoxocity is not precisely understood,
Figure 3. Cisplatin and doxorubicin affect different follicular
cell types. Ovaries were treated with Cisplatin or Doxorubicin. All
unhealthy transitional and primary follicles were further categorized as
unhealthy due to: (A) poor oocyte health; (B) poor granulosa cell health;
or (C) both. Bars denote mean+sem; n= 5 for all groups, stars denote
significant differences relative to control (*p,0.05, **p,0.01,
***p,0.001).
doi:10.1371/journal.pone.0070117.g003
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Figure 4. Representative histological sections of cultured mouse ovaries. (A, B): TUNEL-analysis to determine apoptosis in primordial
follicles. (A): ovary section labelled with TUNEL reaction (green) and counterstained with DAPI (blue). Inset top- and bottom-right magnification
images are of the respective framed areas, illustrating examples of TUNEL positive oocytes (white arrowheads) and TUNEL positive granulosa cell
(white arrow) within follicles identified as at the primordial stage in (B). (B): section in (A) subsequently stained with haematoxylin and eosin. Inset
sections in (A) correspond here to degenerated oocytes (black arrowheads) and degenerated surrounding granulosa cells (black arrow) within
primordial follicles. Scale bar = 50 mm. (C–H): Photomicrographs of haemotoxylin and eosin stained sections from ovaries treated with (C) control, (D)
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but at the cellular level cisplatin affects the metabolic function of
the neuron [41] with the effect partly mediated through the
formation of platinum-DNA-protein crosslinks [42]. It has also
been demonstrated in vitro and in vivo that the formation of
platinum-DNA adducts in the dorsal root ganglion can result in
neuronal apoptosis, despite the fact that these neurones are not
actively dividing [43]. It is very possible that these mechanisms of
affecting non-dividing cells could also be responsible for the oocyte
toxicity that was seen in our study for cisplatin but not
doxorubicin. Neuroprotection during cisplatin treatment has also
been demonstrated following antioxidant treatment [44,45],
indicating that cisplatin may be causing neuronal cell death
through oxidative stress. The role of oxidative stress in the ovary
with regards to primordial and primary follicles is currently
unclear but is another potential mechanism though which cisplatin
could cause follicle loss [46].
Any damage to ovarian stromal cell health could also negatively
impact on follicle reserve. Whilst some studies have suggested that
chemotherapeutic drugs could have a negative effect on the health
of the stroma ([47,48], no consistent quantifiable increase in
stromal pyknosis was found here, with some scattered pyknotic
cells evident, but their presence was very inconsistent among
treatments (results not shown).
Recent work has suggested that the tyrosine kinase inhibitor
imatinib can reduce the toxic effect of cisplatin on the ovary
through its inhibition of c-Abl [17]. Results here provide clear
evidence of a reduction by imatinib of the adverse effect of
cisplatin on follicle health, and show that protection is specific,
with no significant protection found against doxorubicin-induced
damage. Imatinib is thought to provide ovarian protection against
cisplatin damage by inhibiting c-Abl, a tyrosine kinase which
promotes accumulation of p63, the oocyte-specific homologue of
p53: p63 in turn activates cell death following high levels of DNA
damage [17,49,50]. In contrast, doxorubicin upregulates ataxia
telangiectasia mutated (ATM) in the ovary, which is another
activator of cell death in the presence of high levels of DNA
damage [19]. In that study, the authors suggest that ATM can
cause upregulation of p63 not only through independent
3 mg ml21 imatinib, (E) 0.5 mg ml21 cisplatin, (F) cisplatin and imatinib co-treatment, (G) 0.05 mg ml21 doxorubicin and (H) doxorubicin and imatinib
co-treatment. Scale bars represent 25 mm. Examples of a healthy primordial follicle (arrow), healthy growing follicle (black arrowhead) and unhealthy
growing follicle (white arrowhead) are shown.
doi:10.1371/journal.pone.0070117.g004
Figure 5. Effect of cisplatin and doxorubicin on primordial follicles, and on expression of cleaved PARP. (A, B): Analysis of TUNEL-
positive cells within primordial follicles. (A): Total number of primordial follicles, and number of primordial follicles containing TUNEL-positive cells, in
ovaries treated with cisplatin or doxorubicin. (B): TUNEL-positive primordial follicles further categorised into percentage in which the oocyte or the
granulosa cells stained positive. Bars denote mean+sem; n = 4–5; stars denote significant differences relative to control (**P,0.01). (C, D): Cleaved
PARP expression in cisplatin and doxorubicin treated ovaries. Protein expression of cleaved PARP relative to b actin (loading control) in whole
newborn ovaries following 24 h of (C): cisplatin or (D): doxorubicin treatment. Examples of Western blots are shown in Supporting Information,
Figure S3. Bars denote mean+sem; n = 3; stars denote significant differences relative to control (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0070117.g005
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pathways, but also via a c-Abl-dependant pathway, perhaps
explaining the trend towards a protective effect of imatinib found
here (Fig. 6C).
Imatinib treatment alone did not have a deleterious effect on the
ovary, in agreement with some recent work [24,51] although in
contrast to Kerr et al [25] who found no protective effect of
imatinib against cisplatin-induced damage, instead showing
imatinib-induced ovarian damage [25]. The difference between
these studies is possibly due to differences in drug dosages: 10 mM
imatinib, 20 mM cisplatin in Kerr et al [25]; 1 mM imatinib and
7.5 mM cisplatin in Maiani et al [24] and approximately 5 mM
imatinib and 1.67 mM cisplatin here. Interestingly, imatinib alone
increased total follicle number here, due either to inhibition of
follicle death and/or to stimulation of follicle formation: ovaries
were treated with imatinib at the start of the culture period, when
follicle formation still continues in vivo through to postnatal day 3,
with follicle number also increasing in the equivalent period in vitro
(Figure S2). Tyrosine kinase signalling has previously been
implicated to play a positive role in both, leading to increased
primordial follicle formation [52] as well as promoting the survival
of primordial germ cells [53].
In summary, data here show that cisplatin and doxorubicin
both induced follicle loss in cultured mouse ovaries. There was no
evidence of direct effects of either drug on primordial follicle
health, with follicular atresia increased only from within the
growing follicle pool, but each drug induced specific patterns of
damage across and within follicles. One consequence of the
different actions of these two drugs is that any treatments designed
to protect the ovary from chemotherapy-induced damage may
have to be tailored to the specific drug regimens used; this concept
is confirmed by the selective protection afforded by imatinib
mesylate against damage from cisplatin but not from doxorubicin.
Supporting Information
Figure S1 Follicle numbers and composition in control ovaries
cultured for up to six days.
(PDF)
Figure S2 Comparison of TUNEL-positive primordial follicles
in uncultured and cultured ovaries.
(PDF)
Figure S3 Examples of Western blots for the detection of
Cleaved PARP.
(PDF)
Table S1 Individual means, SEMs and p values for data in
Figures.
(PDF)
Figure 6. Imatinib co-treatment with cisplatin, but not doxorubicin, rescues follicle health. Control, cisplatin-treated (0.5 mg ml21) and
doxorubicin-treated (0.05 mg ml21) cultured ovaries were cultured in the presence or absence of imatinib. (A): Percentage of unhealthy follicles
(clear); (B): Total number of follicles (shaded). Bars denote mean+sem; n = 7 for all groups, stars denote significant differences relative to control
(**p,0.01). (C): Pathway by which imatinib could protect the ovary against the damaging effect of cisplatin more effectively than it could against the
damaging effect of doxorubicin.
doi:10.1371/journal.pone.0070117.g006
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